The new offering integrates with existing pathology workflows and enables analysis of archived tissue samples for biomarker discovery.
Panome Bio announced the commercial launch of a metabolomics workflow designed specifically for formalin-fixed paraffin-embedded (FFPE) samples, expanding access to discovery metabolomics for clinical and translational research applications.
The St Louis-based contract research organization developed innovations in sample preparation and data analysis to make traditionally challenging FFPE samples accessible for metabolomic analysis. The technology allows researchers to analyze archived tissues with associated clinical data, enabling retrospective studies and biomarker discovery efforts that were previously limited by sample type constraints.
The new workflow integrates directly into existing pathology laboratory procedures without requiring additional handling protocols or equipment investments, according to the company.
“At Panome Bio, we are constantly striving to provide researchers with the most powerful tools to unravel complex biological questions,” says Edward Weinstein, CEO of Panome Bio, in a release. “By extending our cutting-edge metabolomics platform to include FFPE samples, we are enabling our clients to unlock a wealth of historical biological information, which is particularly valuable for biomarker discovery and understanding disease mechanisms across large, longitudinal cohorts.”
Clinical Laboratory Integration
The FFPE metabolomics capability builds on Panome Bio’s recent Clinical Laboratory Improvement Amendments (CLIA) certification and adds to the company’s existing multi-omic services portfolio, which includes proteomics, transcriptomics, and integrated data analysis.
FFPE samples are a resource in clinical laboratories, as they are the standard method for tissue preservation in pathology workflows. The ability to perform metabolomic analysis on these samples could expand research opportunities for laboratories with extensive tissue archives.
“The ability to perform metabolomics on FFPE samples is a major step forward for the multi-omics field,” says Ginger Zhou, president at GENEWIZ and partner of Panome Bio, in a release. “By adding this crucial layer of metabolomics data to discovery work in FFPE, we can unlock new insights from clinical archives as scientists accelerate paths to patient stratification and more targeted therapies.”
ID 2214236 © Ian Wilson | Dreamstime.com
